Pharmacokinetic disposition of triclabendazole in cattle and sheep; discrimination of the order and the rate of the absorption process of its active metabolite triclabendazole sulfoxide

A comparative pharmacokinetic study was conducted to determine the order and the rate of absorption of triclabendazole (TCBZ) in cattle and sheep. A commercial suspension of TCBZ (Biofasiolex, Biogénesis S.A., Argentina) was administered at a dose rate of 10 mg/kg by the oral route to six Holstein female calves and six Corriedale female sheep. The plasma concentration profiles of the metabolites triclabendazole sulfoxide (TCBZ-SO) and triclabendazole sulfone (TCBZ-SO₂) were analysed by means of the non-compartmental method. The order of the absorption process of the active metabolite, TCBZ-SO, was determined by construction of curves of cumulative absorbed fraction of the drug by means of the Wagner-Nelson method. The appearance of TCBZ-SO in plasma of cattle and sheep resembles the entry of a constant quantity of drug into the organism per unit time. This is explained by the reservoir effect of the rumen, which acts as a biological slow-release system for TCBZ-SO and its precursor TCBZ to the posterior digestive tract where they are absorbed. The plasma concentration profiles of TCBZ-SO in both species were well described by a one-compartment open model with zero-order process of absorption and first-order process of elimination. The values of AUC_0-∞ and C _max of TCBZ-SO did not differ between species, while other kinetic parameters except for λ _z had higher values in calves than in sheep. In the case of TCBZ-SO₂, t _max was the only parameter that did not differ between species, while other kinetic parameters except for λ _z had higher values in calves than in sheep.     

鸡血浆中乙酰氨基阿维菌素HPLC检测法的建立及口服给药后的药代动力学研究

旨在建立鸡血浆中乙酰氨基阿维菌素（EPR）浓度的高效液相色谱（HPLC）检测方法,并进行EPR在鸡体内的药代动力学研究。用甲醇提取血浆中的EPR,并用Sep-Pak C18固相萃取法进行纯化,纯化后的EPR经干燥处理,用三氟乙酸酐和N-甲基咪唑对其进行衍生化,使用荧光HPLC检测。结果表明,在血浆EPR含量为0.1~100 ng/mL范围内,标准曲线线性关系良好,相关系数r=0.9999。检测限（LOD）为0.1 ng/mL,定量限（LOQ）为0.3 ng/mL。批内批间的平均回收率均大于90%,批内变异系数2.81~8.02%,批间变异系数4.32~5.83%。给蛋鸡口服5.0 mg/kg的EPR,EPR在鸡体内的药代动力学参数显示：给药后1.58 h可达最大血药浓度（Cmax）354.27 ng/mL;消除半衰期（T1/2el）为5.52 h;平均滞留时间（MRT）为6.40 h。以上结果说明建立的检测方法灵敏度高、准确度高,干扰少,适用于鸡血浆中EPR含量的检测。药代参数提示EPR在鸡体内的吸收代谢迅速,可较快消除。     

猪链球菌病对肌肉注射多剂量青霉素G药物动力学的影响

本文报道猪链球菌病对肌肉注射多剂量青霉素G钾（15000IU/kg,每隔12h肌注1次,连续给药5次）在猪体内血清浓度和药物动力学影响的研究。通过皮下接种9-10亿个菌落形成单位的猪链球菌,人工诱发猪链球菌病。发病猪给药前的直肠体温比正常时至少升高1.5℃,第一次给药后8h内感染猪的直肠温度仍显著升高（P＜0.05或0.01）,并可观察到其他临床症状。给药后的不同时间间隔从前腔静脉采血,用微生物法测定血清青霉素G的浓度。病猪第一次给药和第五次给药后的血药浓度--时间数据用MCPKP计算机程序处理,均符合一级吸收二室开放模型。病猪第一次及第五次给药的主要药物动力学参数（平均值±标准差）分别是：t#-(1/2α)0.66±0.15及0.59±0.17h;t#-(1/2β)1.87±0.55及2.18±0.97h;t#-(1/2ka)0.35±0.05及0.20±0.09h（P＜0.05）;t#-(max)0.71±0.10及0.48±0.11h（P＜0.05）;C#-(max)7.48±0.97及9.04±0.62IU/ml（P＜0.01）;AUC16.84±1.64及16.42±1.65I U·h/ml,Tcp(ther)11.72±3.33及12.41±3.62h;笔者对引起病猪第一次及第五次给药的某些药物动力学参数有显著差异的原因进行了探讨。     

恩诺沙星及其代谢产物在中华绒螯蟹血淋巴中的比较药代动力学

研究了不同水温(16℃、25℃)、不同给药剂量(10 mg/kg、20 mg/kg)和不同给药方式(肌注、口灌)等条件下,恩诺沙星及其代谢产物环丙沙星在中华绒螯蟹体内的药代动力学,比较了不同条件下药物在蟹血淋巴中的吸收、分布和代谢的差异。结果表明,恩诺沙星在蟹血淋巴中的药-时数据符合开放式二室模型。16℃时以10 mg/kg剂量肌注给药后,恩诺沙星在蟹血淋巴的主要药代动力学参数为:AUC96.818 mg/(L.h),Cmax6.54μg/mL,t1/2α0.851 h,t1/2β95.415 h;25℃时以10 mg/kg剂量肌注给药后,恩诺沙星的主要药代动力学参数为:AUC168.457 mg/(L.h),Cmax7.12μg/mL,t1/2α0.58h,t1/2β88.833 h;25℃时以20 mg/kg剂量肌注给药后,恩诺沙星的主要药代动力学参数为:AUC155.612 mg/(L.h),Cmax11.045μg/mL,t1/2α5.239h,t1/2β88.378 h;25℃时以10 mg/kg剂量口灌给药后,恩诺沙星的主要药代动力学参数为:AUC86.525 mg/(L.h),Cmax3.469μg/mL,t1/2α8.071h,t1/2β61.842 h。不同条件下,恩诺沙星在蟹血淋巴中的主要药代动力学参数差异较大。恩诺沙星的活性代谢产物环丙沙星在各种给药条件下的蟹血淋巴中均能检出,但含量均处于较低值,且药-时数据不能用房室模型拟合,表明恩诺沙星在蟹体内只有极少部分代谢为环丙沙星。     

恩诺沙星及其代谢产物环丙沙星在牙鲆体内代谢消除规律

以80 mg/kg鱼体重对牙鲆单次口灌给药恩诺沙星,给药后在不同的时间点取样,用高效液相色谱荧光检测器检测,研究恩诺沙星及其主要代谢产物环丙沙星在牙鲆体内的代谢消除规律。研究表明,停药后0.25 h,肌肉中恩诺沙星残留量最低。各组织的消除半衰期依次为腮肝脏血液肾脏肌肉,其中肌肉中恩诺沙星消除半衰期最低为67.759 h,消除最快,停药后12 d检测不到恩诺沙星。停药后0.25 h,在牙鲆血液、肝脏、肾脏中均有环丙沙星残留,残留量依次为肝脏肾脏血液,肌肉和鳃中未检出环丙沙星。停药后22 d在血液、肝脏和肾脏3个组织中仍然能够检测出恩诺沙星,但是停药7 d后这3个组织中均检测不出环丙沙星。结果显示,恩诺沙星在牙鲆体内代谢速度较慢,而且只是在一段时间内有脱乙基代谢为环丙沙星的反应发生,但并不是在恩诺沙星消除的全过程都发生,而且代谢物环丙沙星在牙鲆体内的消除速度要比恩诺沙星快。     

3种磺胺类药物在中国对虾(Fenneropenaeus chinensis)体内的药代动力学特征

采用高效液相色谱法研究了3种磺胺类药物在中国对虾体内的药物代谢动力学特征,这3种磺胺类药物包括磺胺二甲嘧啶(SM2)、磺胺嘧啶(SD)及磺胺对甲氧嘧啶(SMD)。实验期间,中国对虾的养殖水温为(24.6±2.4)℃,单次口服3种磺胺类药物的剂量均为100 mg/kg。结果显示,3种磺胺类药物在中国对虾体内的血药经时过程均符合一级吸收二室开放模型,SM2的主要药动学参数T1/2β、AUC、Vd、CL、Tmax、Cmax分别为25.812 h、34.066 mg/L·h、94.553 L/kg、2.608 L/h·kg、2 h、1.07 mg/L;SD的主要药动学参数T1/2β、AUC、Vd、CL、Tmax、Cmax分别为46.446 h、45.39 mg/L·h、97.207 L/kg、1.504 L/h·kg、1 h、1.17 mg/L;SMD的主要药动学参数T1/2β、AUC、Vd、CL、Tmax、Cmax分别为66.296 h、65.917 mg/L·h、40.015 L/kg、0.763 L/h·kg、2 h、2.00 mg/L。结果表明,SMD在中国对虾体内分布比SM2、SD更广泛;中国对虾体内SM2的消除相半衰期最短,SD次之,SMD消除相半衰期最长;3种磺胺类药物在中国对虾体内72 h药物吸收量SMD最高,SD次之,SM2最低;且SMD药物清除率最低,SD次之,SM2药物清除率最高,所以口服3种磺胺类药物72 h中国对虾体内SMD残留最多,SD次之,SM2残留最少。SMD在中国对虾体内药效更加持久,故在不考虑使用成本及毒副作用等其他因素的前提下,比较这3种磺胺类药物的药物代谢动力学特征,更加推荐使用SMD。     

甲砜霉素在鲤鱼中的药代动力学研究

本实验在(26±2)℃的养殖水温下,采用高效液相色谱–串联质谱法(HPLC-MS/MS)研究了以30 mg/(kg·bw)的剂量对鲤鱼(Cyprinus carpio)进行单次投喂药饵后甲砜霉素(Thiamphenicol,TAP)在鲤鱼体内的药物代谢动力学。通过DAS 2.0动力学软件分析TAP在鲤鱼体内的药–时数据,结果表明符合一级吸收二室模型。TAP在肌肉、肾脏、肝脏、鱼皮、鳃、脾脏和血浆各组织的药物达峰时间(T_(peak))分别为16、2、16、8、0、2和16 h,达峰浓度(C_(max))分别为15.6、35.3、12.4、9.0、33.0、11.6 mg/kg和21.0 mg/L;药–时曲线下面积(AUC)分别为1084.5、1578.1、777.3、541.1、0.1、478.1 mg/(kg·h)和485.1 mg/(L·h),消除半衰期(t_(1/2β))分别为11.4、100.2、54.2、41.1、69.5、38.0和71.9 h。TAP在鲤鱼体内各组织的分布和消除速率相差较大;在肾脏中的药物达峰时间短且达峰浓度高于其他组织,其消除半衰期也明显高于其他组织,推测肾脏是鲤鱼体内TAP蓄积和代谢的主要器官。按照农业部《动物性食品中兽药最高残留限量》文件规定,TAP在水产动物中最高残留限量(MRL)不得高于50μg/kg,本研究中,肌肉、肾脏、肝脏、鱼皮、脾脏和血浆的TAP残留量低于MRL的时间分别从第16、16、12、12、12、10和12天开始,将肌肉和肾脏作为TAP药物残留的靶组织,建议休药期不得低于16 d。     

Pharmacokinetics of marbofloxacin after a single oral dose to loggerhead sea turtles (Caretta caretta)

The single-dose disposition kinetics of marbofloxacin (MBX) were determined in clinically healthy loggerhead sea turtles (n = 5) after oral (PO) administration of 2 mg kg⁻¹ bodyweight. Marbofloxacin plasma concentrations were determined by DAD–HPLC (LOD/LOQ 0.015/0.05 μg ml⁻¹). Data were subjected to non-compartmental analysis. Following PO administration, marbofloxacin achieved maximum plasma concentrations of 11.66 ± 2.53 mg L⁻¹ at 15.00 ± 3.00 h. The absence of general adverse reactions in the turtles of the study, and the favourable pharmacokinetic properties (long half-life and high maximum plasma concentration) of MBX administered PO at the single-dose of 2 mg kg⁻¹ suggest the possibility of its safe and effective clinical use in loggerhead sea turtles.     

Effect of age and gender in the pharmacokinetics of albendazole and albendazole sulphoxide enantiomers in goats

The kinetics of albendazole metabolites and albendazole sulphoxide enantiomers were studied in 2- and 14-month-old female and male goats, after a single oral dose administration (10 mg/kg) of an albendazole formulation. Blood samples from the jugular vein were collected at 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48 and 54 h post-treatment and analyzed using a high performance liquid chromatography method. In all groups the area under the plasma concentration-time curve (AUC) and peak concentration (C_max) values of (+)-ABZSO were significantly higher than those of (−)-ABZSO. The AUC and C_max values obtained for (+)-ABZSO and (−)-ABZSO in adult animals were higher compared to the results in young animals, showing significant differences except for (+)-ABZSO in female animals. In young animals, independently of gender, the C_max appeared earlier compared to adult animals. The mean residence time (MRT) values were shorter in young animals compared to adult animals for all compounds analyzed. No sex-related differences were found for any of the parameters calculated except for the (+)-ABZSO from adult animals.     

Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment

We investigated the effects of hepatic and renal impairment on the pharmacokinetics of enrofloxacin in Sprague-Dawley rats. Experimental hepatic and renal failure were induced by carbon tetrachloride (CCL₄) and 5/6 nephrectomy, respectively. After intravenous dosing of enrofloxacin (10 mg/kg), plasma concentrations of enrofloxacin were measured using liquid chromatograph/mass spectrometry. There was no significant effect of hepatic impairment on enrofloxacin pharmacokinetics. However, renal impairment markedly prolonged elimination half life (t_1/2λz) of enrofloxacin (P < 0.05), comparing with respective control. Total body clearance (Cl_b) and volume of distribution at steady state (V_ss) were significantly decreased (P < 0.05) by renal impairment. In conclusion, these results suggested that renal impairment could affect the pharmacokinetics of enrofloxacin.